PharmaShots Weekly Snapshot (March 04-08, 2019)
1.Bayer Submits EUs Marketing Authorization Application to EMA for Darolutamide
Published: 08 Mar,2019 |Tags: Bayer, Submits, EU, Marketing Authorization Application, EMA, Darolutamide2
2. Zeiss CIRRUS HD-OCT Receives FDAs 510 (k) Clearance for Epithelial Thickness Mapping (ETM)
Published: 08 Mar,2019 |Tags: Zeiss, CIRRUS HD-OCT, Receives, FDA, 510 (k), Clearance, Epithelial Thickness Mapping, ETM
Published: 08 Mar,2019 |Tags: Janssen, Reports, Positive, Results, Rilpivirine, Cabotegravir, P-III, ATLAS, FLAIR, Studies, HIV
4. Oncternal Therapeutics Reverse Merges with GTx
Published: 08 Mar,2019 |Tags: GTx, Signs, Reverse, Merger, Agreement, Oncternal Therapeutics
Published: 08 Mar,2019 |Tags: Shionogi, Signs, Development, Commercialization, Agreement, Akili, AKL-T01, AKL-T02
6. Baxters Eptifibatide Receives the US FDAs Approval for Cardiovascular Diseases
Published: 07 Mar,2019 |Tags: Baxter, Eptifibatide, Receives, the US, FDA, Approval, Cardiovascular, Diseases
Published: 07 Mar,2019 |Tags:Alnylam, Reports, Result, Givosiran, P-III, ENVISION, Study, Acute Hepatic Porphyria, AHP
8. Vertex Reports Positive Results of Triple Combination Therapy in P-III Studies for Cystic Fibrosis
Published: 07 Mar,2019 |Tags: Vertex, Reports, Results, Triple Combination Therapy, P-III, Studies, Cystic Fibrosis
Published: 07 Mar,2019 |Tags: BeiGene, Ambrx, Enters, Worldwide, Research, Development, Collaboration, Develop, Novel, Biologics
Published: 07 Mar,2019 |Tags: Allergan, Reports, Results, Rapastinel, Four, P-III, RAP-MD, Studies, Major Depressive Disorders, MDD
11. Pfizer Exercised its Option to License AnTolRx's Immune Tolerance Therapy for Type 1 Diabetes (T1D)
Published: 06 Mar,2019 |Tags: Pfizer, Exercised, Option to License, AnTolRx, Immune Tolerance Therapy, Type 1 Diabetes, T1D
12. Pacira to Acquire MyoScience to Expand its Post-Surgical Portfolio
Published: 06 Mar,2019 |Tags: Pacira, Acquire, MyoScience, Expand, Post-Surgical, Portfolio, Exparel, Iovera
Published: 06 Mar,2019 |Tags: Genentech, Announces, FDA, Acceptance, sNDA, Xofluza, baloxavir marboxil, Patients, Influenza
14. Accelerons ACE-083 Receives FDAs ODD for Charcot Marie Tooth Disease (CMT)
Published: 06 Mar,2019 |Tags: Acceleron, ACE-083, Receives, FDA, ODD, Charcot Marie Tooth Disease, CMT, FSHD
15. Celgenes Fedratinib Receives FDAs Priority Review to NDA Filing for Myelofibrosis
Published: 06 Mar,2019 |Tags: ? Celgene, Fedratinib, Receives, FDA, Priority Review, Myelofibrosis, NDA
Published: 05 Mar,2019 |Tags: ProMab Biotechnologies, Signs, Worldwide, License, Agreement, NantKwest, Develop, Ab, Multiple Myeloma
17. Bioxcel, Nektar and Merck KGaA in a Triple Collaboration for Pancreatic Cancer
Published: 05 Mar,2019 | Tags: BioXcel Therapeutics, BTI, Expands, Clinical Collaboration, Nektar, Addition, Merck KGaA, Pfizer
Published: 05 Mar,2019 |Tags: Ascendis Pharma, Reports, Results, TransCon Growth Hormone, P-III, Height, Study,Growth Hormone Deficiency, GHD, Children
19. Clovis Oncology Launches Rubraca (rucaparib) for Women with Relapsed Ovarian Cancer in Germany
Published: 05 Mar,2019 |Tags: Clovis Oncology, Launches, Rubraca, rucaparib, Women, Relapsed, Ovarian Cancer, Germany
Published: 05 Mar,2019 |Tags: Verastem Oncology, Reports, Results, Copiktra, Duvelisib, P-III, DUO, Study, Patients, R/R, CLL/SLL
21. Biogen to Acquire Nightstar Therapeutics for $800M
Published: 04 Mar,2019 | Tags: Biogen, Acquire, Nightstar Therapeutics, $800M, NSR-REP1, NSR-RPGR
Published: 04 Mar,2019 | Tags: Novartis, Reports, Results, Cosentyx, secukinumab, P-III Study, Patients, Moderate, Severe, Plaque Psoriasis, China
23. Lupus Therapeutics Signs a Research Agreement with Takeda for its TAK-079
Published: 04 Mar,2019 |Tags: Lupus Therapeutics, Signs, Research, Agreement, Takeda, TAK-079
Published: 04 Mar,2019 |Tags: Sanofi, Zynquista, sotagliflozin, Dupixent, dupilumab, Receives, CHMP, Recommendation, Type 1 Diabetes, Asthma